Founding shareholders and British biotech take control of BioLigands
Danish firm carries out r&d into treatments for obesity and related metabolic disorders
The founding shareholders in Danish firm BioLigands, together with UK-based biotech Bridge BioResearch, have taken over the equity previously held by Southern Danish Innovation.
Odense-based BioLigands offers consultancy, custom and natural compounds services, internal research and development programmes for the treatment of obesity and related metabolic disorders and supports basic research.
One molecule identified by BioLigands is now entering Phase IIa trials with a listed Swiss biotech company. In addition the firm has identified and developed active ingredients for a pan-European manufacturer of ‘power shots’.
‘We have looked at numerous projects in lifestyle related diseases, but some of the approaches made by BioLigands ApS are truly remarkable.
‘We have known the founding shareholders and ceo Esben Flindt for quite a long time, and when this opportunity came up we made the final decision to invest,’ said Søren Stenderup, ceo of Bridge BioResearch, which was established in 2004 by an Anglo/Danish management team to identify leading projects within diabetes and obesity. The firm manages projects from facilities in Copenhagen, while admin and finance is undertaken from the London office
‘The project is a perfect strategic fit to our business especially as BioLigands is also a partner in an EU-funded consortium together with Bridge BioResearch.’
Klaus Holmsberg, from Southern Danish Innovation, added: ‘Our early investigations indicated a project with a strong possibility for bringing new life to developments of novel pharmacological and nutraceutical treatments of lifestyle induced diseases.
‘The founding shareholders together with Bridge BioResearch form an interesting and international player offering attractive and synergistic partner qualities. We have accomplished our mission and the company in our view is better suited for the future being run by the founding shareholders.’
